Cell:百瀚和妇女医院揭开了帕金森病标志物α-突触核蛋白的双面角色

2022-07-16 “生命科学前沿”公众号 “生命科学前沿”公众号

“这是一种被当前疗法所靶向的蛋白质,但其功能一直难以捉摸,传统上认为α-突触核蛋白在与细胞膜的结合和被称为囊泡的运输结构中发挥了作用,但williamhill asia 的研究表明α-突触核蛋白正在扮演着双重角色。”

帕金森病(PD)的标志之一是在脑中积累称为α-突触核蛋白的蛋白质。二十多年来,α-突触核蛋白一直是研究人员,临床医生和制造商关注的焦点。但α-突触核蛋白的功能尚不明确。由百瀚和妇女医院,哈佛干细胞研究所以及Broad研究所的研究人员领导的一项新研究为研究α-突触核蛋白的作用带来了希望,揭开了一个与PD和相关病症有关的新功能,研究结果发表在Cell期刊上。

通讯作者Vikram Khurana博士表示:“williamhill asia 的研究为一种已知处于帕金森病和相关疾病发展中心的蛋白质提供了新的见解。”他是百瀚和妇女医院及哈佛医学院神经病学系运动障碍科主任以及 Ann Romney神经系统疾病中心的首席研究员。“这是一种被当前疗法所靶向的蛋白质,但其功能一直难以捉摸,传统上认为α-突触核蛋白在与细胞膜的结合和被称为囊泡的运输结构中发挥了作用,但williamhill asia 的研究表明α-突触核蛋白正在扮演着双重角色。

Vikram Khurana博士

百瀚和妇女医院及哈佛医学院神经病学系运动障碍科主任

Ann Romney神经系统疾病中心的首席研究员

Khurana及其同事的最初线索来自α-突触核蛋白毒性的酵母和果蝇模型,并通过对人类细胞,病人来源的神经元和人类遗传学的研究得到证实。研究小组发现,与囊泡相互作用的α-突触核蛋白的同一部分也与“P体”结构结合,P体是细胞中通过信使RNA(mRNA)调节基因表达的机制。在诱导多能干细胞衍生的神经元中,从具有α-突触核蛋白基因突变的帕金森病患者身上产生的P体,其生理结构和功能会丧失,并且mRNA调节异常。来自患者死后大脑的组织样本中也发生了同样的情况。人类基因分析支持了这些发现与疾病的相关性:在P体基因中积累突变的患者似乎患帕金森病的风险更高。

双面的α-突触核蛋白

作者将α-突触核蛋白描述为一种“切换开关”,可调节两种非常不同的功能:囊泡运输和基因表达。在疾病状态下,这种平衡被打破。这些发现对PD治疗的发展具有潜在的意义。作者指出,需要更清楚哪些P体机制部件可能是治疗干预的最佳目标。正在进行的遗传研究旨在确定哪些患者可能最适合这种干预,以及这种新发现的途径在多大程度上有助于对整个帕金森病患者的疾病风险和疾病进展的研究。

论文主要作者,百瀚Ann Romney神经系统疾病中心神经病学系的Erinc Hallacli博士表示:“如果williamhill asia 想要能够开发针对α-突触核蛋白的治疗方法,williamhill asia 需要了解这种蛋白质的作用以及降低其水平或活性的潜在后果。这项研究提供了重要信息,以填补williamhill asia 对该蛋白质的知识空白,这对临床转化非常有益。”

关于美国麻总百瀚

麻总百瀚(Mass General Brigham)由美国波士顿的麻省总医院(Mass General Hospital)与百瀚和妇女医院(Brigham and Women's Hospital)所创立,这两家分别是哈佛医学院规模最大的教学医院和美国顶尖的学术医学中心。麻总百瀚总共有16家成员机构,其中包括williamhill asia 世界知名的医学中心、排名靠前的专科医院以及美国规模最大、最优秀的康复系统之一。

为加强全球的医疗服务,williamhill asia 的各家医院前所未有地统一作为一个单一医疗保健系统一起共同行动。随着这一变化,麻总百瀚将带领williamhill asia 的系统开展国际化合作,促进与同样在改变世界的领先医疗机构的合作。

原始出处:

Hallacli E et al. The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. Cell DOI: 10.1016/j.cell.2022.05.008.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1962792, encodeId=899f1962e92cc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 21 06:58:07 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872464, encodeId=4cfd18e24646d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 20 03:58:07 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986103, encodeId=c4c119861033d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Sep 18 21:58:07 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841913, encodeId=c9d8184191343, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Mar 23 06:58:07 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233289, encodeId=272f12332897d, content=希望今后能在此基础上可以实现转化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Mon Jul 18 21:45:15 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478823, encodeId=222f14e8823fc, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524523, encodeId=0c9c1524523e7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae911610611, createdName=yankaienglish, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232901, encodeId=00731232901c5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jul 17 06:49:14 CST 2022, time=2022-07-17, status=1, ipAttribution=)]
    2023-02-21 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1962792, encodeId=899f1962e92cc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 21 06:58:07 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872464, encodeId=4cfd18e24646d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 20 03:58:07 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986103, encodeId=c4c119861033d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Sep 18 21:58:07 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841913, encodeId=c9d8184191343, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Mar 23 06:58:07 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233289, encodeId=272f12332897d, content=希望今后能在此基础上可以实现转化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Mon Jul 18 21:45:15 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478823, encodeId=222f14e8823fc, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524523, encodeId=0c9c1524523e7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae911610611, createdName=yankaienglish, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232901, encodeId=00731232901c5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jul 17 06:49:14 CST 2022, time=2022-07-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1962792, encodeId=899f1962e92cc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 21 06:58:07 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872464, encodeId=4cfd18e24646d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 20 03:58:07 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986103, encodeId=c4c119861033d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Sep 18 21:58:07 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841913, encodeId=c9d8184191343, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Mar 23 06:58:07 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233289, encodeId=272f12332897d, content=希望今后能在此基础上可以实现转化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Mon Jul 18 21:45:15 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478823, encodeId=222f14e8823fc, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524523, encodeId=0c9c1524523e7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae911610611, createdName=yankaienglish, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232901, encodeId=00731232901c5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jul 17 06:49:14 CST 2022, time=2022-07-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1962792, encodeId=899f1962e92cc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 21 06:58:07 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872464, encodeId=4cfd18e24646d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 20 03:58:07 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986103, encodeId=c4c119861033d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Sep 18 21:58:07 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841913, encodeId=c9d8184191343, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Mar 23 06:58:07 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233289, encodeId=272f12332897d, content=希望今后能在此基础上可以实现转化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Mon Jul 18 21:45:15 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478823, encodeId=222f14e8823fc, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524523, encodeId=0c9c1524523e7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae911610611, createdName=yankaienglish, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232901, encodeId=00731232901c5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jul 17 06:49:14 CST 2022, time=2022-07-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1962792, encodeId=899f1962e92cc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 21 06:58:07 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872464, encodeId=4cfd18e24646d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 20 03:58:07 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986103, encodeId=c4c119861033d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Sep 18 21:58:07 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841913, encodeId=c9d8184191343, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Mar 23 06:58:07 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233289, encodeId=272f12332897d, content=希望今后能在此基础上可以实现转化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Mon Jul 18 21:45:15 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478823, encodeId=222f14e8823fc, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524523, encodeId=0c9c1524523e7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae911610611, createdName=yankaienglish, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232901, encodeId=00731232901c5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jul 17 06:49:14 CST 2022, time=2022-07-17, status=1, ipAttribution=)]
    2022-07-18 海上飘星

    希望今后能在此基础上可以实现转化!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1962792, encodeId=899f1962e92cc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 21 06:58:07 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872464, encodeId=4cfd18e24646d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 20 03:58:07 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986103, encodeId=c4c119861033d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Sep 18 21:58:07 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841913, encodeId=c9d8184191343, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Mar 23 06:58:07 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233289, encodeId=272f12332897d, content=希望今后能在此基础上可以实现转化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Mon Jul 18 21:45:15 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478823, encodeId=222f14e8823fc, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524523, encodeId=0c9c1524523e7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae911610611, createdName=yankaienglish, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232901, encodeId=00731232901c5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jul 17 06:49:14 CST 2022, time=2022-07-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1962792, encodeId=899f1962e92cc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 21 06:58:07 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872464, encodeId=4cfd18e24646d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 20 03:58:07 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986103, encodeId=c4c119861033d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Sep 18 21:58:07 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841913, encodeId=c9d8184191343, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Mar 23 06:58:07 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233289, encodeId=272f12332897d, content=希望今后能在此基础上可以实现转化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Mon Jul 18 21:45:15 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478823, encodeId=222f14e8823fc, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524523, encodeId=0c9c1524523e7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae911610611, createdName=yankaienglish, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232901, encodeId=00731232901c5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jul 17 06:49:14 CST 2022, time=2022-07-17, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1962792, encodeId=899f1962e92cc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 21 06:58:07 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872464, encodeId=4cfd18e24646d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 20 03:58:07 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986103, encodeId=c4c119861033d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Sep 18 21:58:07 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841913, encodeId=c9d8184191343, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Mar 23 06:58:07 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233289, encodeId=272f12332897d, content=希望今后能在此基础上可以实现转化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Mon Jul 18 21:45:15 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478823, encodeId=222f14e8823fc, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524523, encodeId=0c9c1524523e7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae911610611, createdName=yankaienglish, createdTime=Mon Jul 18 07:58:07 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232901, encodeId=00731232901c5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jul 17 06:49:14 CST 2022, time=2022-07-17, status=1, ipAttribution=)]
    2022-07-17 学医无涯

    学习一下

    0

相关威廉亚洲官网

Movement disorders:帕金森病:黑质中的铁沉积,如何随时间变化?

在开始使用多巴胺能药物治疗之前,黑质铁较低,然后在整个疾病过程中不断增加,直到晚期达到平稳

Annals Neurology:突触核蛋白,在脑脊液中的和大脑中有何关联?

CSF αSyn-SAA在合并病理和非LBD诊断的情况下可靠地识别弥漫性αSyn病理患者的αSyn种子

Movement disorders:帕金森患者,糖尿病可加速其进展

T2DM与帕金森病的疾病进展速度有关,突出了这两种疾病之间的互动。

Movement disorders 同济大学;帕金森病:短链脂肪酸减少,或因肠-血屏障受损

PD患者的粪便和血浆SCFAs的改变与GBB受损有关,并可能因便秘而加重。

movement disorders:孤立的快速眼动睡眠,语言异常或可提示认知障碍

语言学特征可能为检测iRBD受试者中由前驱神经变性引起的认知能力下降提供了可靠的自动方法